OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Denise Niewerth, Gerrit Jansen, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2014) Vol. 18, pp. 18-35
Closed Access | Times Cited: 169
Denise Niewerth, Gerrit Jansen, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2014) Vol. 18, pp. 18-35
Closed Access | Times Cited: 169
Showing 1-25 of 169 citing articles:
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 591
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 591
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 389
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 389
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, et al.
Cancer and Metastasis Reviews (2017) Vol. 36, Iss. 4, pp. 561-584
Closed Access | Times Cited: 299
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, et al.
Cancer and Metastasis Reviews (2017) Vol. 36, Iss. 4, pp. 561-584
Closed Access | Times Cited: 299
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Maya Bar-Zeev, Yoav D. Livney, Yehuda G. Assaraf
Drug Resistance Updates (2017) Vol. 31, pp. 15-30
Closed Access | Times Cited: 287
Maya Bar-Zeev, Yoav D. Livney, Yehuda G. Assaraf
Drug Resistance Updates (2017) Vol. 31, pp. 15-30
Closed Access | Times Cited: 287
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 254
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 254
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Sabrina Dallavalle, Vladimir Dobričić, Loretta Lazzarato, et al.
Drug Resistance Updates (2020) Vol. 50, pp. 100682-100682
Open Access | Times Cited: 241
Sabrina Dallavalle, Vladimir Dobričić, Loretta Lazzarato, et al.
Drug Resistance Updates (2020) Vol. 50, pp. 100682-100682
Open Access | Times Cited: 241
The Influence of Metabolism on Drug Response in Cancer
Esther A. Zaal, Celia R. Berkers
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 223
Esther A. Zaal, Celia R. Berkers
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 223
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
Nicola Amodio, Maria Angelica Stamato, Giada Juli, et al.
Leukemia (2018) Vol. 32, Iss. 9, pp. 1948-1957
Open Access | Times Cited: 222
Nicola Amodio, Maria Angelica Stamato, Giada Juli, et al.
Leukemia (2018) Vol. 32, Iss. 9, pp. 1948-1957
Open Access | Times Cited: 222
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong, Zuodong Qin, Weidong Zhang, et al.
Drug Resistance Updates (2020) Vol. 49, pp. 100681-100681
Closed Access | Times Cited: 210
Jinyun Dong, Zuodong Qin, Weidong Zhang, et al.
Drug Resistance Updates (2020) Vol. 49, pp. 100681-100681
Closed Access | Times Cited: 210
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yaël Cohen, Mor Zada, Shuang-Yin Wang, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 491-503
Open Access | Times Cited: 184
Yaël Cohen, Mor Zada, Shuang-Yin Wang, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 491-503
Open Access | Times Cited: 184
Exosomes and their role in tumorigenesis and anticancer drug resistance
Neta Milman, Lana Ginini, Ziv Gil
Drug Resistance Updates (2019) Vol. 45, pp. 1-12
Closed Access | Times Cited: 178
Neta Milman, Lana Ginini, Ziv Gil
Drug Resistance Updates (2019) Vol. 45, pp. 1-12
Closed Access | Times Cited: 178
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Pérez-Ruíz, Ignacio Melero, Joanna Kopecka, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100718-100718
Open Access | Times Cited: 164
Elisabeth Pérez-Ruíz, Ignacio Melero, Joanna Kopecka, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100718-100718
Open Access | Times Cited: 164
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Shigeki Ito
Cancers (2020) Vol. 12, Iss. 2, pp. 265-265
Open Access | Times Cited: 157
Shigeki Ito
Cancers (2020) Vol. 12, Iss. 2, pp. 265-265
Open Access | Times Cited: 157
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Esther A. Zaal, Wei Wu, Gerrit Jansen, et al.
Cancer & Metabolism (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 143
Esther A. Zaal, Wei Wu, Gerrit Jansen, et al.
Cancer & Metabolism (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 143
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Xin Wang, Magdalena Mazurkiewicz, Ellin‐Kristina Hillert, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 142
Xin Wang, Magdalena Mazurkiewicz, Ellin‐Kristina Hillert, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 142
Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug
Xiaonan Zhang, Karthik Selvaraju, Amir Ata Saei, et al.
Biochimie (2019) Vol. 162, pp. 46-54
Open Access | Times Cited: 138
Xiaonan Zhang, Karthik Selvaraju, Amir Ata Saei, et al.
Biochimie (2019) Vol. 162, pp. 46-54
Open Access | Times Cited: 138
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
Guillem Paniagua, Lenka Bešše, Nan Li, et al.
Leukemia (2016) Vol. 30, Iss. 11, pp. 2198-2207
Open Access | Times Cited: 132
Guillem Paniagua, Lenka Bešše, Nan Li, et al.
Leukemia (2016) Vol. 30, Iss. 11, pp. 2198-2207
Open Access | Times Cited: 132
Positioning of proteasome inhibitors in therapy of solid malignancies
Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen
Cancer Chemotherapy and Pharmacology (2017) Vol. 81, Iss. 2, pp. 227-243
Open Access | Times Cited: 128
Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen
Cancer Chemotherapy and Pharmacology (2017) Vol. 81, Iss. 2, pp. 227-243
Open Access | Times Cited: 128
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Nir Shahar, Sarit Larisch
Drug Resistance Updates (2020) Vol. 52, pp. 100712-100712
Closed Access | Times Cited: 124
Nir Shahar, Sarit Larisch
Drug Resistance Updates (2020) Vol. 52, pp. 100712-100712
Closed Access | Times Cited: 124
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Thorsten Stiewe, Tali E. Haran
Drug Resistance Updates (2018) Vol. 38, pp. 27-43
Closed Access | Times Cited: 119
Thorsten Stiewe, Tali E. Haran
Drug Resistance Updates (2018) Vol. 38, pp. 27-43
Closed Access | Times Cited: 119
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
The bad seed: Cancer stem cells in tumor development and resistance
Elle Koren, Yaron Fuchs
Drug Resistance Updates (2016) Vol. 28, pp. 1-12
Closed Access | Times Cited: 103
Elle Koren, Yaron Fuchs
Drug Resistance Updates (2016) Vol. 28, pp. 1-12
Closed Access | Times Cited: 103
Nanomedicine to target multidrug resistant tumors
Élise Lepeltier, Patrícia Rijo, Flavio Rizzolio, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100704-100704
Open Access | Times Cited: 97
Élise Lepeltier, Patrícia Rijo, Flavio Rizzolio, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100704-100704
Open Access | Times Cited: 97
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
Tatiana V. Denisenko, Irina Sorokina, Vladimir Gogvadze, et al.
Drug Resistance Updates (2015) Vol. 24, pp. 1-12
Closed Access | Times Cited: 96
Tatiana V. Denisenko, Irina Sorokina, Vladimir Gogvadze, et al.
Drug Resistance Updates (2015) Vol. 24, pp. 1-12
Closed Access | Times Cited: 96
